What is EXPAREL?
EXPAREL is an FDA-approved, long-lasting, non-opioid analgesic that, as part of a multimodal
approach to pain management, provides effective postsurgical pain relief and helps reduce
the need for opioids after surgery.
EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL works locally at the surgical site and uses the DepoFoam® drug delivery technology, which encapsulates bupivacaine in multivesicular liposomes. Following injection, DepoFoam particles gradually release bupivacaine over time as the lipid membranes are absorbed, prolonging the duration of action of bupivacaine.2,3 More than two
million patients have been treated with EXPAREL since 2012.
Has EXPAREL been studied in oral surgery?
The safety, efficacy and pharmacokinetics of EXPAREL were evaluated in the Infiltration Trial
In Third Molar Extraction Observing The Analgesic Effect of EXPAREL (INNOVATE) trial—a
randomized, double-blind, placebo-controlled study of local administration of EXPAREL for
prolonged postsurgical analgesia in patients undergoing bilateral third molar extraction.
EXPAREL was shown to be safe in the safety population